You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
University of Texas MD Anderson Cancer Center
Headquarters:Houston, TX
Year Founded:1941
Status:Academic
Biopharma related deals can be found by searching the organization's name in the BCIQ Deals Module*.*desktop version only

BioCentury | Apr 13, 2019

Tools & Techniques

ctDNA inches toward new applications

...Health Inc. (NASDAQ:GH), Redwood City, Calif. Inivata Ltd., Cambridge, U.K. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Texas MD Anderson Cancer Center...

BioCentury | May 01, 2021

BioCentury | Mar 30, 2021

Deals

Deerfield’s growing umbrella: Data Byte

...Center, The Rockefeller University and Weill Cornell Medicine. And in 2017, the VC partnered with The University of Texas MD Anderson Cancer Center...

BioCentury | Feb 23, 2021

Distillery Therapeutics

Epigenetic enzyme WHSC1L1 as a squamous cell lung cancer target

...Pawel K. Mazur, The University of Texas MD Anderson Cancer Center, Houston, Texasemail: pkmazur@mdanderson.orgCONTACT: Or Gozani, Stanford University, Stanford, Calif.email: ogozani@stanford.edu Claire Quang Stanford University University of Texas MD Anderson Cancer Center University...

BioCentury | Feb 13, 2021

Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...rise of complex modalities, is shaping the way MD Anderson builds partnerships and develops new assets.University of Texas MD Anderson Cancer Center’s...
...Tumor necrosis factor receptor superfamily member 10b YAP1 (YAP) - Yes-associated protein 1 Karen Tkach Tuzman University of Texas MD Anderson Cancer Center Mirati...

BioCentury | Oct 21, 2020

Deals

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

...research administration and industry relations at the University of Texas MD Anderson Cancer Center.Examples...
...remains managing partner of Louisiana-based BVM Capital. Paul Bonanos University of Texas MD Anderson Cancer Center...

BioCentury | Oct 17, 2020

Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...NASDAQ:ALLO) entered a five-year collaboration with The University of Texas MD Anderson Cancer Center...

BioCentury | Sep 05, 2020

Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...fusion inhibitors is a plus for patients, University of Texas MD Anderson Cancer Center’s...

BioCentury | Aug 13, 2020

Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...Francisco, Memorial Sloan Kettering Cancer Center and University of Texas MD Anderson Cancer Center...

BioCentury | Jul 15, 2020

Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...to run biomarker based cancer trials Sanofi (Euronext:SAN; NASDAQ:SNY) announced a five-year collaboration with the University of Texas MD Anderson Cancer Center...
...Brand), FX006 (Compound #), Sustained-release triamcinolone acetonide (Generic), triamcinolone acetonide extended-release injectable suspension (Informal), Zilretta (Other) Sanofi University of Texas MD Anderson Cancer Center Cytokinetics...

BioCentury | Feb 28, 2020

Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...board. Allison is professor and chair of immunology and executive director of immunotherapy at the University of Texas MD Anderson Cancer Center...

BioCentury | Feb 06, 2020

Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

...and fewer safety risks. Though the data come from only 11 patients, a study from University of Texas MD Anderson Cancer Center...
...of patients was small, efficacy signals from a CD19-targeted CAR NK cell therapy from The University of Texas MD Anderson Cancer Center...
...cell death 1 ligand 1 TCR - T cell receptor Lauren Martz, Senior Editor Takeda Pharmaceutical Co. Ltd. University of Texas MD Anderson Cancer Center CD19...

BioCentury | Jan 25, 2020

Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

...manufacturing as very important.” Rick Fair, Bellicum On Tuesday, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said the University of Texas MD Anderson Cancer Center...
...Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Bio-Techne Corp. Fresenius SE & Co. KGaA Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Nationwide...

BioCentury | Jan 22, 2020

Company News

JV to combine technologies into one gene and cell therapy manufacturing platform

...of lower doses (see "Gene Therapy 2.0" ). Separately, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said the University of Texas MD Anderson Cancer Center...
...Programmed cell death 1 TGF-β - Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Fresenius...

BioCentury | Jan 13, 2020

Politics & Policy

Academic sponsors lag industry in reporting clinical trial results

...Medicine as “habitual violators” of reporting requirements. Other institutions with poor track records include the University of Texas MD Anderson Cancer Center...

BioCentury | Dec 13, 2019

Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer Center...
...MLL - Myeloid/lymphoid or mixed-lineage leukemia BioCentury Staff Syndax Pharmaceuticals Inc. Biogen Inc. University of Pennsylvania Medidata Solutions Inc. Aptose Biosciences Inc. University of Texas MD Anderson Cancer Center Neurimmune...

BioCentury | Dec 06, 2019

Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...therapies before infusion to direct the cells to the tumor upon infusion. Teams from The University of Texas MD Anderson Cancer Center...

BioCentury | Dec 02, 2019

Politics & Policy

Patient, medical groups urge quick confirmation of Hahn as FDA commissioner

...full Senate will vote confirm Hahn before year end. “As Chief Medical Executive at The University of Texas MD Anderson Cancer Center...

BioCentury | Nov 20, 2019

Politics & Policy

FDA commissioner nominee Hahn sidesteps questions on importation, new approval standards

...into what he hopes to accomplish. He asserted that there are "striking similarities" between the University of Texas MD Anderson Cancer Center...

BioCentury | Nov 16, 2019

Regulation

Stephen Hahn’s road to White Oak

...of Pennsylvania School of Medicine from 1996 to January 2015, when he moved to the University of Texas MD Anderson Cancer Center...
...integrity and independence at a time when faith in public institutions is crumbling. Steve Usdin, Washington Editor University of Texas MD Anderson Cancer Center U.S...

BioCentury | Nov 06, 2019

Politics & Policy

HELP chair endorses Hahn for FDA commissioner, sets Nov. 20 confirmation hearing

...following a meeting with Hahn. Alexander cited Hahn’s experience as chief medical executive at the University of Texas MD Anderson Cancer Center...

BioCentury | Nov 06, 2019

Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...MD Anderson, Takeda partner for CAR NK cell therapies The University of Texas MD Anderson Cancer Center partnered with Takeda Pharmaceutical Co...
...Li, Staff Writer and Jonathan Block, Associate Editor BCX7353 Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) University of Texas MD Anderson Cancer Center Myriad...

BioCentury | Nov 05, 2019

Product Development

Senti taps tumor-homing MSCs for lead engineered immunotherapy

...to patients’ ovarian tumors and secreted the cytokine locally. Andreeff is professor of medicine at University of Texas MD Anderson Cancer Center...
...β; IL-12 - Interleukin-12; IL-21 - Interleukin-21 Karen Tkach Tuzman, Associate Editor Senti Biosciences Inc. Massachusetts Institute of Technology University of Texas MD Anderson Cancer Center Interleukin-12...

BioCentury | Nov 01, 2019

Politics & Policy

Trump administration shifts Sharpless to make way for Hahn

...see “Trump to Nominate Hahn as FDA Commissioner” ). Hahn, chief medical executive at The University of Texas MD Anderson Cancer Center...
...and the role of FDA in facilitating it.” Steve Usdin, Washington Editor U.S. Food and Drug Administration (FDA) University of Texas MD Anderson Cancer Center Ned...

BioCentury | Oct 17, 2019

Preclinical News

Oct. 17 Preclinical Quick Takes: Miromatrix, Mayo extend vascular function in liver graft scaffold; plus James Allison-MD Anderson, Northwestern and Eleusis

...Autoimmune antibodies as biomarkers of checkpoint inhibitor toxicity James Allison and his colleagues at the University of Texas MD Anderson Cancer Center...
...protein subunit α L; ITM2B (BRI2) - Integral membrane protein 2B BioCentury Staff Northwestern University Lysosomal Therapeutics Inc. Mayo Clinic University of Texas MD Anderson Cancer Center Miromatrix...

BioCentury | Oct 01, 2019

Politics & Policy

Trump to nominate Hahn as FDA commissioner

...FDA commissioner, sources familiar with the decision told BioCentury. Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center...

BioCentury | Sep 13, 2019

Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...development leader for oncology, effective Sept. 23. She was a professor of medicine at the University of Texas MD Anderson Cancer Center...

BioCentury | Sep 05, 2019

Politics & Policy

FDA commissioner search narrowed to three

...Acting Commissioner Ned Sharpless, the White House is considering Stephen Hahn, chief medical executive, the University of Texas MD Anderson Cancer Center...
...Commissioners, Patient Groups Endorse Sharpless” ). Steve Usdin, Washington Editor Harvard Medical School U.S. Food and Drug Administration (FDA) University of Texas MD Anderson Cancer Center Alexa...

BioCentury | Aug 28, 2019

Company News

Immatics reels in $75M from Celgene in first cell therapy deal

...from its 2015 launch of a joint venture company, Immatics US Inc. (Houston, Texas) with University of Texas MD Anderson Cancer Center...

BioCentury | Aug 22, 2019

Politics & Policy

Biomedical stakeholders caution against limiting U.S.-China collaboration

...to U.S. competitiveness in the life sciences (see "Fearmongering About China" ). In April, The University of Texas MD Anderson Cancer Center...

BioCentury | Aug 22, 2019

Distillery Therapeutics

Fecal microbiome-based therapy for PDAC

...DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer University of Texas MD Anderson Cancer Center researchers showed that fecal microbiota transplants derived from long-term...
...published online Aug. 08, 2019 doi:10.1016/j.cell.2019.07.008 CONTACT: Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas email: fmcallister@mdanderson.org Hongjiang Li University of Texas MD Anderson Cancer Center Pancreatic...

BioCentury | Aug 20, 2019

Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

...Emory University School of Medicine. WP1066 is in an ongoing Phase I trial led by University of Texas MD Anderson Cancer Center...

BioCentury | Aug 15, 2019

Preclinical News

Aug. 15 Preclinical Quick Takes: Implicating the tumor microbiome in cancer; plus computational pain classification, multiplexed CRISPR and LUCA

...MD Anderson links microbiome to pancreatic cancer University of Texas MD Anderson Cancer Center researchers suggested the tumor microbiome can predict survival...
...LUCA Planning to Tackle Infections in Women" ). Hongjiang Li, Staff Writer ETH Zurich LUCA Biologics Inc. University of Pennsylvania University of Texas MD Anderson Cancer Center CRISPR...

BioCentury | Aug 12, 2019

Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

...2020. Boehringer, MD Anderson in cancer collaboration Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with the University of Texas MD Anderson Cancer Center...
...member 10b BioCentury Staff bavituximab (3G4, Tarvacin) CX-8998 Keytruda, pembrolizumab (MK-3475, lambrolizumab) AC Immune S.A. Boehringer Ingelheim GmbH OncXerna Therapeutics Inc. University of Pennsylvania University of Texas MD Anderson Cancer Center Cavion...

BioCentury | Aug 09, 2019

Tools & Techniques

The next frontier for single-cell analysis

...the set of targets and mechanisms that are most important in a given tumor. The University of Texas MD Anderson Cancer Center...
...Brunswick, N.J. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Texas MD Anderson Cancer Center...

BioCentury | Aug 08, 2019

Distillery Therapeutics

RNF2 inhibition to treat prostate cancer

...CONTACT: Filippo G. Giancotti, MD Anderson Cancer Center, University of Texas, Houston, Texas e-mail: fggiancotti@mdanderson.org Inhua Muijrers-Chen University of Texas MD Anderson Cancer Center Cytotoxic...

BioCentury | Aug 05, 2019

Preclinical News

Guardant data another step forward for tissue-agnostic diagnostics

...The test has Expedited Access Pathway (EAP) designation from FDA. Researchers from Guardant Health and University of Texas MD Anderson Cancer Center...
...Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Guardant Health Inc. University of Texas MD Anderson Cancer Center cell-free...

BioCentury | Aug 03, 2019

Emerging Company Profile

Bringing CAR T to India

...One of the physicians at the center has received training in CAR T at The University of Texas MD Anderson Cancer Center...
...BSE:532523), Bangalore, India Columbia University, New York N.Y. Mazumdar Shaw Cancer Centre, Bangalore, India The University of Texas MD Anderson Cancer Center Steve...

BioCentury | Aug 01, 2019

Distillery Therapeutics

Sensitizing cancer to checkpoint inhibitors by targeting the non-coding RNA LINC01139

...Leng Han, University of Texas Health Science Center, Houston, Texas e-mail: leng.han@uth.tmc.edu CONTACT: Chunru Lin, University of Texas MD Anderson Cancer Center...
...clin2@mdanderson.org CONTACT: Liuqing Yang, same affiliation as above e-mail: lyang7@mdanderson.org Sandi Wong University of Texas Health Science Center University of Texas MD Anderson Cancer Center Cytotoxic...

BioCentury | Jul 19, 2019

Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

...in immune cells to treat cancer. Removing sugar residues to improve anti-PD-L1 therapy response predictions University of Texas MD Anderson Cancer Center...
...protein 1 Mary Romeo, Assistant Editor SM07883 Blade Therapeutics Inc. Dana-Farber Cancer Institute EdiGene Inc. Johns Hopkins University Peking University Quentis Therapeutics Inc. Samumed LLC University of Texas MD Anderson Cancer Center Weill...

BioCentury | Jul 18, 2019

Distillery Therapeutics

Inhibiting EZH2 for myeloma-associated bone loss

...published online May 29, 2019 doi:10.1126/scitranslmed.aau9087 CONTACT: Jing Yang, University of Texas MD Anderson Cancer Center, Houston, Texas email: jiyang@mdanderson.org Hongjiang Li University of Texas MD Anderson Cancer Center Enhancer...

BioCentury | Jun 14, 2019

Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...for Medicine, is professor and chair of immunology and executive director of immunotherapy at the University of Texas MD Anderson Cancer Center...

BioCentury | Jun 01, 2019

Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...Solid tumors CCDC6 was a RET proto-oncogene (RET) upstream partner in 24.2% of RET fusions University of Texas MD Anderson Cancer Center...

BioCentury | May 31, 2019

Translation in Brief

New target for Oncoceutics' GPCR-targeting compounds

...breast cancer (TNBC), glioma and leukemia. But according to Micheal Andreeff, professor of medicine at University of Texas MD Anderson Cancer Center...
...subunit; DRD2 - Dopamine D2 receptor Sandi Wong, Staff Writer ONC201 Oncoceutics Inc. University of North Carolina at Chapel Hill University of Texas MD Anderson Cancer Center Caseinolytic...

BioCentury | May 25, 2019

Politics & Policy

Emory ousts researchers, citing China ties

...at least 55 institutions, including Emory, asking them to investigate specific individuals. Last month, the University of Texas MD Anderson Cancer Center...
...Researchers After NIH Flags Threats of Foreign Influence" ). Mary Romeo, Staff Writer Emory University National Institutes of Health University of Texas MD Anderson Cancer Center...

BioCentury | May 20, 2019

Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma

...et al. Sci. Transl. Med. ; published online May 8, 2019 doi:10.1126/scitranslmed.aau1167 CONTACT: Linghua Wang, University of Texas MD Anderson Cancer Center...
...same affiliation as above email: miwang@mdanderson.org Claire Quang IACS-010759, IACS-10759 Imbruvica (Brand), PCI-32765 (Compound #), ibrutinib (Generic), Imbruvica (Other) University of Texas MD Anderson Cancer Center Mitochondrial...

BioCentury | May 10, 2019

Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

...the case in a 2015 study . In a review article , a team from University of Texas MD Anderson Cancer Center...

BioCentury | May 08, 2019

Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

...CDH4 could help treat triple-negative breast cancer (TNBC) CSIR-Indian Institute of Chemical Biology ; The University of Texas MD Anderson Cancer Center...

BioCentury | May 01, 2019

Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

...MD Anderson findings could make radiation possible for pancreatic cancer Researchers at University of Texas MD Anderson Cancer Center reported findings suggesting...
...cell death 1 ligand 1 Mary Romeo, Staff Writer roxadustat (ASP1517, FG-4592) FibroGen Inc. Harvard University Sana Biotechnology Inc. Sigilon Therapeutics Inc. University of Texas MD Anderson Cancer Center CD47 Factor...

BioCentury | Apr 19, 2019

Politics & Policy

MD Anderson ousting researchers after NIH flags threats of foreign influence

...The University of Texas MD Anderson Cancer Center said it is ousting three tenured faculty members after investigations revealed they violated NIH...
...Theft of U.S. Research Due to Lax Disclosure Rules" ). Mary Romeo, Staff Writer National Institutes of Health University of Texas MD Anderson Cancer Center...

BioCentury | Apr 10, 2021

Product Development

MD Anderson AACR data in heavily pretreated lymphoma patients offer long-awaited lift to Affimed

...from Seagen Inc. (NASDAQ:SGEN).The data, from a University of Texas MD Anderson Cancer Center-sponsored...
...data on AFM24 at the conference. Lauren Martz Affimed N.V. University of Texas MD Anderson Cancer Center AACR...

BioCentury | Apr 10, 2019

Tools & Techniques

Microbiome makes its mark outside the gut

...melanoma to combined immune checkpoint blockade, while high levels of Lactobacillales could help predict non-response. University of Texas MD Anderson Cancer Center...
...oral microbiome changes could help predict risk of human papillomavirus (HPV)-negative oral squamous cell carcinoma. University of Texas MD Anderson Cancer Center...
...pancreatic tumor microbiome could help identify pancreatic patients likely to survive longer than five years. University of Texas MD Anderson Cancer Center...

BioCentury | Apr 10, 2019

Distillery Therapeutics

UBR7 and CDH4 as targets for triple-negative breast cancer

...Siddhartha Roy, CSIR-Indian Institute of Chemical Biology, Kolkata, India email: roysiddhartha@iicb.res.in CONTACT: Kunal Rai, The University of Texas MD Anderson Cancer Center...
...Chandrima Das, Saha Institute of Nuclear Physics, Kolkata, India email: chandrima.das@saha.ac.in Claire Quang Saha Institute of Nuclear Physics University of Texas MD Anderson Cancer Center Cadherin...

BioCentury | Apr 04, 2019

Clinical News

Jounce reports detailed data backing tumor-agnostic approach

...these trials are expected next year. CTLA-4 pioneer Jim Allison, chair of immunology at the University of Texas MD Anderson Cancer Center...

BioCentury | Mar 29, 2019

Targets & Mechanisms

AACR moves in a myeloid direction

...It also shows chemotherapies can modulate the breast tumor microbiome ( No. 2835 ). A University of Texas MD Anderson Cancer Center...
...of Cancer Research (AACR) annual meeting is the National Cancer Institute (NCI), followed closely by University of Texas MD Anderson Cancer Center...
...of Chicago, Chicago, Ill. University of Florida, Gainesville, Fla. University of Tennessee , Knoxville, Tenn. University of Texas MD Anderson Cancer Center...

BioCentury | Mar 25, 2019

Distillery Therapeutics

IL-17RD or inhibition of ZEB1 to sensitize lung cancer to MEK inhibition

...CONTACT: Don L. Gibbons, University of Texas MD Anderson Cancer Center, Houston, Texas email: dlgibbon@mdanderson.org Claire Quang mocetinostat (MGCD0103, MG-0103) selumetinib (ARRY-886, AZD6244, ARRY-142886, MK-5618) University of Texas MD Anderson Cancer Center Histone...

BioCentury | Mar 23, 2019

Tools & Techniques

A frequentist and a Bayesian walk into a trial

...the ability to update information as data accrues,” added Donald Berry, a professor at the University of Texas MD Anderson Cancer Center...

BioCentury | Mar 11, 2019

Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

...testing could include approved drugs and compounds in development. Seres is already partnered with the University of Texas MD Anderson Cancer Center...

BioCentury | Mar 09, 2019

Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

...these trials are expected next year. CTLA-4 pioneer Jim Allison, chair of immunology at the University of Texas MD Anderson Cancer Center...

BioCentury | Mar 04, 2019

Distillery Therapeutics

USP11 identified as a prostate cancer target

...South Korea email: ssong1@sch.ac.kr CONTACT: Min Sup Song, The University of Texas MD Anderson Cancer Center, Houston, Texas email: msong1@mdanderson.org Claire Quang Soonchunhyang University University of Texas MD Anderson Cancer Center Ubiquitin...

BioCentury | Feb 14, 2019

Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

...PGD could help treat renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC) The University of Texas MD Anderson Cancer Center...

BioCentury | Jan 18, 2019

Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

...The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's...
...Suzhou, China University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Jennie Walters APG-115 APG-1252 APG-1387, iap inhibitor APG-2575 HQP1351, GZD824, D824 NBTXR3, PEP503 Ascentage Pharma Group International University of Texas MD Anderson Cancer Center Nanobiotix...

BioCentury | Jan 16, 2019

Distillery Therapeutics

Cancer

...steps include identifying and testing PGD inhibitors in animal models of hereditary leiomyomatosis RCC. The University of Texas MD Anderson Cancer Center...
...et al. Cell Rep. ; published online Jan. 8, 2019 doi:10.1016/j.celrep.2018.12.043 CONTACT: Yuting Sun, The University of Texas MD Anderson Cancer Center...
...Houston, Texas email: ysun8@mdanderson.org CONTACT: Joseph R. Marszalek, same affiliation as above email: jrmarszalek@mdanderson.org Claire Quang IACS-010759, IACS-10759 University of Texas MD Anderson Cancer Center Mitochondrial...

BioCentury | Jan 15, 2019

Politics & Policy

MSKCC says senior execs may not hold industry board seats

...actively manage and, in some cases, eliminate identified conflicts of interest," a spokesperson told BioCentury. University of Texas MD Anderson Cancer Center...

BioCentury | Jan 07, 2019

Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

...the arms embargo against China (see "CFIUS Waiting Game" ). Jennie Walters APG-115 APG-1252 APG-1387, iap inhibitor APG-2575 Ascentage Pharma Group International University of Texas MD Anderson Cancer Center B...

BioCentury | Dec 21, 2018

Clinical News

No breakthrough therapy designation for Spectrum's poziotinib

...Spectrum’s breakthrough therapy designation application included interim data from a Phase II trial sponsored by University of Texas MD Anderson Cancer Center...

BioCentury | Dec 21, 2018

Product R&D

Cell therapies seek solid ground

...of targets, said Cassian Yee, a professor in the Department of Melanoma Medical Oncology at University of Texas MD Anderson Cancer Center...
...National Cancer Institute (NCI), Bethesda, Md. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa. University of Texas MD Anderson Cancer Center...

BioCentury | Dec 14, 2018

Emerging Company Profile

ExCellThera’s safer allogeneic transplants

...Guy Sauvageau and Anne Marinier University collaborators: University of Montreal, University of Toronto, Stanford University, University of Texas MD Anderson Cancer Center...
...University of Toronto, Toronto, Ontario Sandi Wong, Staff Writer ECT-001 ExCellThera Inc. Gamida Cell Ltd. Magenta Therapeutics Inc. Stanford University University of Montreal University of Texas MD Anderson Cancer Center University...

BioCentury | Dec 14, 2018

Finance

Mission: Mainstream

...delivering or manufacturing new therapies.” Clientele include more than a dozen academic centers such as University of Texas MD Anderson Cancer Center...

BioCentury | Dec 08, 2018

Regulation

Path to opioid-free pain relief

...after discharge. Maria Suarez-Almazor, a professor in the department of general internal medicine at the University of Texas MD Anderson Cancer Center...
...Medicine, Stanford, Calif. Tufts University School of Medicine, Boston, Mass. University of Pennsylvania, Philadelphia, Pa. University of Texas MD Anderson Cancer Center...

BioCentury | Dec 01, 2018

Product Development

Cell therapy momentum at ASH

...Safety data for 2 patients; No disease response at low dose in 2 patients 4373 University of Texas MD Anderson Cancer Center...

BioCentury | Nov 30, 2018

Targets & Mechanisms

Revving up metabolism at ASH 2018

...target protein to the proteasome for degradation rather than inhibiting it directly. Three abstracts from University of Texas MD Anderson Cancer Center...
...University of Minnesota, Minneapolis, Minn. University of North Carolina at Chapel Hill, Chapel Hill, N.C. University of Texas MD Anderson Cancer Center...

BioCentury | Nov 16, 2018

Clinical News

Fecal transplant could treat toxicity common to checkpoint inhibitors

...inhibitor-associated colitis. Wang is an assistant professor of gastroenterology, hepatology and nutrition at MD Anderson. University of Texas MD Anderson Cancer Center...
...microbiota transplant Business: Gastrointestinal, Transplant Indication: Treat refractory immune checkpoint inhibitor-associated colitis in cancer patients Chris Lieu University of Texas MD Anderson Cancer Center fecal...

BioCentury | Nov 12, 2018

Clinical News

Fecal transplant could treat toxicity common to checkpoint inhibitors

...Opdivo (Other) Yervoy (Brand), MDX-CTLA-4 (Compound #), MDX-010 (Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) University of Texas MD Anderson Cancer Center Cytotoxic...

BioCentury | Nov 01, 2018

Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

...of CCNI variants could help diagnose breast, melanoma and ovarian cancers Immatics Biotechnologies GmbH ; University of Texas MD Anderson Cancer Center...

BioCentury | Oct 26, 2018

Regulation

Learning the limits of limited use

...said panelist Scott Evans, an associate professor in the department of pulmonary medicine at the University of Texas MD Anderson Cancer Center...
...Bridgewater, N.J. Loyola University Medical Center, Maywood, Ill. Oregon Health & Science University, Portland, Ore. University of Texas MD Anderson Cancer Center...

BioCentury | Oct 11, 2018

Translation in Brief

Cancer antigens from RNA edits

...A team from Immatics Biotechnologies GmbH and University of Texas MD Anderson Cancer Center has shown that cancer antigens generated via post-transcriptional...
...that the antigens’ presence on tumors presents a new opportunity for cancer immunotherapy. Mary Romeo, Staff Writer University of Texas MD Anderson Cancer Center Immatics...

BioCentury | Oct 02, 2018

Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

...the Parker Institute for Cancer Immunotherapy and the executive director of the Immunotherapy Platform at University of Texas MD Anderson Cancer Center...

BioCentury | Sep 21, 2018

Financial News

DePinho's STAT3 company Tvardi raises $9M series A

...to treat cancer and inflammatory and fibrotic diseases. Ronald DePinho, professor and former president of University of Texas MD Anderson Cancer Center...
...Texas Mary Romeo Alexandria Venture Investments Baylor College of Medicine Cancer Prevention and Research Institute of Texas (CPRIT) Tvardi Therapeutics Inc. University of Texas MD Anderson Cancer Center Signal...

BioCentury | Sep 20, 2018

Financial News

DePinho's STAT3 company Tvardi raises $9M series A

...to treat cancer and inflammatory and fibrotic diseases. Ronald DePinho, professor and former president of University of Texas MD Anderson Cancer Center...
...a CEO. Mary Romeo Baylor College of Medicine Cancer Prevention and Research Institute of Texas (CPRIT) StemMed Ltd. Tvardi Therapeutics Inc. University of Texas MD Anderson Cancer Center Signal...

BioCentury | Sep 14, 2018

Financial News

OncoResponse to move into clinic with $40M series B

...PD-L1 inhibitors. OncoResponse, a JV launched in 2015 by Theraclone Sciences Inc. (Seattle, Wash.) and University of Texas MD Anderson Cancer Center...

BioCentury | Sep 11, 2018

Financial News

OncoResponse to move into clinic with $40M series B

...PD-L1 inhibitors. OncoResponse, a JV launched in 2015 by Theraclone Sciences Inc. (Seattle, Wash.) and University of Texas MD Anderson Cancer Center...

BioCentury | Aug 24, 2018

Politics & Policy

NIH investigating foreign influence in U.S.-funded research

...the NIH grant application, and has asked the institutions to look into the matter. A University of Texas MD Anderson Cancer Center...
...June, Trump said he plans to use CFIUS as a vehicle to protect U.S. innovation. Mary Romeo University of Texas MD Anderson Cancer Center National...

BioCentury | Aug 17, 2018

Finance

MD Anderson’s blooms

...$31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center...
...talks with MD Anderson regarding additional spinouts. Chris Lieu, Staff Writer Accelerator Life Science Partners Alzheimer's disease Magnolia Neurosciences Corp. neuropathy University of Texas MD Anderson Cancer Center...

BioCentury | Aug 17, 2018

Financial News

MD Anderson launches neuroscience newco with $31M series A

...The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York...
...bring a few products into the clinic. Magnolia Neurosciences Corp., New York, N.Y. Chris Lieu Magnolia Neurosciences Corp. University of Texas MD Anderson Cancer Center Accelerator...

BioCentury | Aug 13, 2018

Financial News

MD Anderson launches neuroscience newco with $31M series A

...The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York...

BioCentury | Aug 10, 2018

Company News

Jazz, MD Anderson partner to evaluate hematologic cancer therapies

...using CombiPlex technology. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Shannon Lehnbeuter Vyxeos (CPX-351) University of Texas MD Anderson Cancer Center Jazz...

BioCentury | Aug 10, 2018

Company News

Genprex to evaluate effect of Oncoprex on checkpoint inhibition with MD Anderson

...Genprex Inc. (NASDAQ:GNPX) will sponsor a preclinical program at the University of Texas MD Anderson Cancer Center (Houston, Texas) aimed at evaluating...
...MD Anderson. Genprex Inc. (NASDAQ:GNPX), Austin, Texas University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Shannon Lehnbeuter Oncoprex (fus1 nanoparticles) Genprex Inc. University of Texas MD Anderson Cancer Center Tumor...

BioCentury | Jul 19, 2018

Tools & Techniques

Immunotherapy Matchmaking

...center, and Patrick Hwu, who heads its division of cancer medicine, to create the The University of Texas MD Anderson Cancer Center...
...analysis, and whole genome and exome sequencing (see “Table: Platform Pieces”). Table: Platform pieces The University of Texas MD Anderson Cancer Center...
...Pfizer Inc. (NYSE:PFE), New York, N.Y. Polaris Group, Taipei, Taiwan Roche (SIX:ROG; OTCQX:RHHBY), Basel Switzerland University of Texas MD Anderson Cancer Center...

BioCentury | Jun 22, 2018

Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

...investigator-led study. Ziopharm spokesperson David Connolly declined to disclose details. A trial start at the University of Texas MD Anderson Cancer Center...
...Oncology Inc. (NASDAQ:ZIOP), Boston, Mass. Product: Point-of-care CD19-targeted CAR T cells Business: Cancer Allison Johnson Precigen Inc. Merck KGaA University of Texas MD Anderson Cancer Center Ziopharm...

BioCentury | Jun 18, 2018

Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

...investigator-led study. Ziopharm spokesperson David Connolly declined to disclose details. A trial start at the University of Texas MD Anderson Cancer Center...
...targets for solid tumors and hematologic malignancies. Intrexon added $0.31 to $16.46 Monday. Allison Johnson Precigen Inc. Merck KGaA University of Texas MD Anderson Cancer Center Ziopharm...

BioCentury | Jun 16, 2018

Product Development

MATCH’s long game

...It has since begun accepting assays performed by Foundation Medicine Inc., Caris Life Sciences Inc., University of Texas MD Anderson Cancer Center...
...Bethesda, Md. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Society for Immunotherapy of Cancer (SITC), Milwaukee, Wis. University of Texas MD Anderson Cancer Center...

BioCentury | Jun 01, 2018

Company News

Amgen, MD Anderson partner to develop T cell immunotherapies

...Amgen Inc. (NASDAQ:AMGN) and the University of Texas MD Anderson Cancer Center partnered to develop Amgen's early stage immunotherapies including CAR T...
...collaborations are undisclosed. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Mary Romeo Amgen Inc. University of Texas MD Anderson Cancer Center...

BioCentury | May 31, 2018

Company News

Amgen, MD Anderson collaborate on BiTE, CAR T therapies

...Amgen Inc. (NASDAQ:AMGN) and the University of Texas MD Anderson Cancer Center partnered to develop Amgen's early stage immunotherapies including CAR T...
...that financial details and specific therapies or programs included in the collaborations are undisclosed. Mary Romeo Amgen Inc. University of Texas MD Anderson Cancer Center...

BioCentury | May 30, 2018

Distillery Therapeutics

Cancer

...published online May 15, 2018 doi:10.1158/2326-6066.CIR-17-0655 CONTACT: Seyed Moghaddam, The University of Texas MD Anderson Cancer Center, Houston, Texas email: smoghadd@mdanderson.org Chris Lieu University of Texas MD Anderson Cancer Center Interleukin-22...

BioCentury | May 17, 2018

Preclinical News

Inhibiting IL-22 could treat KRAS-mutant lung cancer

...A study published in Cancer Immunology Research from scientists at the University of Texas MD Anderson Cancer Center suggests inhibiting IL-22 could...
...database, there are no candidates targeting IL-22 or its receptor in development to treat cancer. Chris Lieu University of Texas MD Anderson Cancer Center Interleukin-22...

BioCentury | May 03, 2018

Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

...sample, cell culture and mouse studies suggest inhibiting ZRANB1 could help treat breast cancer. The University of Texas MD Anderson Cancer Center...

BioCentury | Apr 24, 2018

Distillery Therapeutics

Cancer

...The University of Texas MD Anderson Cancer Center, Houston, Texas email: zhangpeijing@hust.edu.cn CONTACT: Li Ma, same affiliation as above email: lma4@mdanderson.org Sandi Wong University of Texas MD Anderson Cancer Center Zinc...

BioCentury | Apr 20, 2018

Product Development

Lessons from the ECHO chamber

...as performance status and blood-based biomarkers of treatment response. Berry is a professor at the University of Texas MD Anderson Cancer Center...

BioCentury | Apr 19, 2018

Preclinical News

Increased ubiquitination of EZH2 or ALK for cancer therapies

...elimination of EZH2 could be more efficacious. In the Cell Reports paper , researchers at University of Texas MD Anderson Cancer Center...
...Healthcare S.A. (Lugano, Switzerland) market Zykadia to treat non-small cell lung cancer (NSCLC). Sandi Wong Ceritinib Zykadia Dana-Farber Cancer Institute University of Texas MD Anderson Cancer Center Anaplastic...